4//SEC Filing
ROMP CHARLES R 4
Accession 0000899243-23-020646
CIK 0001060736other
Filed
Dec 14, 7:00 PM ET
Accepted
Dec 15, 6:16 PM ET
Size
6.7 KB
Accession
0000899243-23-020646
Insider Transaction Report
Form 4
Seagen Inc.SGEN
ROMP CHARLES R
EVP, Commercial
Transactions
- Disposition to Issuer
Performance Stock Units
2023-12-14−1,747→ 0 total→ Common stock (1,747 underlying)
Footnotes (2)
- [F1]Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").
- [F2]Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a "Company August 2023 PSU") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance.
Documents
Issuer
Seagen Inc.
CIK 0001060736
Entity typeother
Related Parties
1- filerCIK 0001809717
Filing Metadata
- Form type
- 4
- Filed
- Dec 14, 7:00 PM ET
- Accepted
- Dec 15, 6:16 PM ET
- Size
- 6.7 KB